健帆生物：公司实践案例获《商业向善案例集2025》收录

Core Insights - Jianfan Bio's case study has been included in the "Business for Good Case Collection 2025," highlighting its commitment to social responsibility and innovation in the medical technology sector [1] - The case focuses on over 20 years of "responsibility evolution," emphasizing the company's efforts to break foreign medical technology monopolies through independent innovation in blood purification technology [1] - The initiative includes innovations in payment systems, enhancing grassroots medical capabilities, and promoting industry collaboration to make technology more accessible [1] Company Initiatives - Jianfan Bio initiated the "919 Uremia Care Day" to build social consensus and create a closed loop of "original innovation - technology accessibility - social advocacy" [1] - The company exemplifies how a domestic enterprise in the medical technology field can empower social welfare through core technology, fulfilling the dual mission of "treating diseases and saving lives" while contributing to industrial growth [1] Event Details - The forum where the case study was presented was guided by the China Association for International Exchange of Personnel and organized by the Hainan Asia Public Welfare Research Institute along with several other institutions [1] - The event attracted over 600 participants from 16 countries and regions, including government representatives, international organization leaders, philanthropists, entrepreneurs, and scholars, to discuss Asian public welfare development [1] - The live broadcast of the forum garnered over 900,000 views, indicating significant interest in global sustainable development challenges [1]